Infant Bacterial Therapeutics AB (publ)

OM:IBT B Rapporto sulle azioni

Cap. di mercato: SEK 468.8m

Infant Bacterial Therapeutics Gestione

Gestione criteri di controllo 2/4

Infant Bacterial Therapeutics Il CEO è Staffan Stromberg, nominato in Jan2013, e ha un mandato di 11.83 anni. la retribuzione annua totale è SEK 5.33M, composta da 57.9% di stipendio e 42.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.79% delle azioni della società, per un valore di SEK 3.72M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.5 anni e 7.5 anni.

Informazioni chiave

Staffan Stromberg

Amministratore delegato

SEK 5.3m

Compenso totale

Percentuale dello stipendio del CEO57.9%
Mandato del CEO11.8yrs
Proprietà del CEO0.8%
Durata media del management1.5yrs
Durata media del Consiglio di amministrazione7.5yrs

Aggiornamenti recenti sulla gestione

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

May 02
Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 02
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

May 02
Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Apr 03
Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

Sep 16
Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

May 11
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Sep 23
We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Dec 15
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 25
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

May 06
We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

Feb 07
Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Staffan Stromberg rispetto agli utili di Infant Bacterial Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-SEK 142m

Mar 31 2024n/an/a

-SEK 128m

Dec 31 2023SEK 5mSEK 3m

-SEK 123m

Sep 30 2023n/an/a

-SEK 122m

Jun 30 2023n/an/a

-SEK 99m

Mar 31 2023n/an/a

-SEK 69m

Dec 31 2022SEK 6mSEK 3m

-SEK 65m

Sep 30 2022n/an/a

-SEK 42m

Jun 30 2022n/an/a

-SEK 34m

Mar 31 2022n/an/a

-SEK 65m

Dec 31 2021SEK 5mSEK 3m

-SEK 45m

Sep 30 2021n/an/a

-SEK 55m

Jun 30 2021n/an/a

-SEK 74m

Mar 31 2021n/an/a

-SEK 73m

Dec 31 2020SEK 4mSEK 2m

-SEK 72m

Sep 30 2020n/an/a

-SEK 73m

Jun 30 2020n/an/a

-SEK 65m

Mar 31 2020n/an/a

-SEK 44m

Dec 31 2019SEK 3mSEK 2m

-SEK 46m

Sep 30 2019n/an/a

-SEK 43m

Jun 30 2019n/an/a

-SEK 40m

Mar 31 2019n/an/a

-SEK 32m

Dec 31 2018SEK 3mSEK 2m

-SEK 41m

Sep 30 2018n/an/a

-SEK 26m

Jun 30 2018n/an/a

-SEK 22m

Mar 31 2018n/an/a

-SEK 37m

Dec 31 2017SEK 3mSEK 1m

-SEK 36m

Compensazione vs Mercato: La retribuzione totale di Staffan ($USD 498.42K ) è superiore alla media delle aziende di dimensioni simili nel mercato Swedish ($USD 239.32K ).

Compensazione vs guadagni: La retribuzione di Staffan è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Staffan Stromberg (57 yo)

11.8yrs

Mandato

SEK 5,327,000

Compensazione

Mr. Staffan Stromberg, Ph.D. Eng has been the Chief Executive Officer at Infant Bacterial Therapeutics AB (publ) since 2013. Mr. Stromberg served as Director at Genetic Analysis AS since October 28, 2020 u...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Staffan Stromberg
Chief Executive Officer11.8yrsSEK 5.33m0.79%
SEK 3.7m
Maria Ekdahl
Chief Financial Officer2.2yrsNessun dato0.031%
SEK 146.4k
Anders Kronström
Chief Operating Officer6.8yrsSEK 500.00k0.083%
SEK 389.5k
Thomas Schnitzer
Chief Scientific Officerless than a yearNessun datoNessun dato
Sanjiv Sharma
Head of Medical Affairsless than a yearNessun datoNessun dato
Jonas Rastad
Chief Medical Officerless than a yearNessun datoNessun dato

1.5yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di IBT B non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Peter Rothschild
Chairman13.8yrsSEK 727.00kNessun dato
Margareta Hagman
Independent Director9.2yrsSEK 153.00k0.039%
SEK 183.9k
Eva Idén
Independent Director7.5yrsSEK 153.00k0.0042%
SEK 19.5k
Kristina Nygren
Independent Director6.5yrsSEK 153.00k0.00074%
SEK 3.5k
Anthon Jahreskog
Independent Director7.5yrsSEK 193.00k0.18%
SEK 844.6k

7.5yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di IBT B sono considerati esperti (durata media dell'incarico 7.5 anni).